Filing Flows › ResMed (RMD) › Q2 FY26
ResMed (RMD) Q2 FY26 earnings results (second quarter fiscal 2026)
10-Q filed Jan 30, 2026
ResMed (RMD) reported revenue of $1.4B for the second quarter fiscal 2026 (Q2 FY26), +11% from a year earlier and +7% from the quarter before. Operating margin was 34.6%, net earnings $393M (27.6% of revenue).
ResMed, Q2 FY26: revenue $1.4B (+11% year over year), operating margin 34.6%, net earnings $393M, operating cash flow $340M. The chart follows the revenue to costs, profit and cash.
| Q2 FY26 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.4B | +7% | +11% |
| Gross profit | $879M | +7% | +17% |
| Operating profit | $492M | +10% | +18% |
| Net earnings | $393M | +13% | +14% |
| Operating cash flow | $340M | -26% | +10% |
| Free cash flow | $311M | -25% | +8% |
What changed
Revenue was $1.4B in Q2 FY26, up 11% year over year and up 7% from the previous quarter. Sleep and Breathing Health was the largest line at 88% of revenue. Sleep and Breathing Health added $0.13B year over year (up 12%), 93% of the total change.
Gross margin was 61.8%, up 3.2 points from a year earlier. Operating profit was $0.49B, a 34.6% margin (up 2.0 points year over year). Of the extra revenue versus a year earlier, 53% reached operating profit, above the 33% margin then. Operating expenses grew 16% against revenue growth of 11%. The fastest-growing cost line was Other operating costs (+60%). Net earnings were $0.39B, up 14% year over year. The effective tax rate was 20.9%.
Operating cash flow was $0.34B (up 10% year over year), 87% of net earnings. Non-cash charges added back $0.05B of depreciation and amortization and $0.03B of share-based compensation. Working capital and other items used $0.13B. Capital expenditures of $0.03B left free cash flow of $0.31B.
Questions
What was ResMed's revenue in the second quarter fiscal 2026?
ResMed (RMD) reported revenue of $1.4B for the second quarter fiscal 2026 (Q2 FY26), +11% from a year earlier and +7% from the quarter before.
Was ResMed profitable in the second quarter fiscal 2026?
Operating profit was $492M (34.6% of revenue) and net earnings $393M.
Source: ResMed 10-Q on SEC EDGAR.